Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Hanlin Yin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6622-4301; OpenAlex author ID A5036689552. Sources: OpenAlex.

Their work

Papers
22 (first author 8, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
58
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 5 papers · 2023: 1 paper · 2024: 1 paper · 2025: 4 papers · 2026: 4 papers

Papers 22

  1. Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Center Study. Co-author DOI 10.1002/advs.202515952↗
  2. RASA2 Promotes Pancreatic Cancer Metastasis by Activating TGFβ-Dependent Non-canonical Hedgehog Signaling. Co-author DOI 10.1158/0008-5472.can-26-0333↗
  3. Gut microbiota and pancreatic cancer: tumorigenesis, progression, and clinical applications. Co-author DOI 10.20892/j.issn.2095-3941.2025.0650↗
  4. M1 Macrophage-derived TNF-α Promotes Pancreatic Cancer Ferroptosis via p38 MAPK-ACSL4 Pathway. First author DOI 10.2174/0115665240374551250630075409↗
  5. The Crosstalk with CXCL10-Rich Tumor-Associated Mast Cells Fuels Pancreatic Cancer Progression and Immune Escape. Co-author DOI 10.1002/advs.202417724↗
  6. The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor-Intrinsic PD-1/c-MET Signaling in Pancreatic Cancer. First author DOI 10.1002/advs.202500806↗
  7. Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. Co-author DOI 10.1016/j.isci.2024.111693↗
  8. Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pan… Co-author DOI 10.1097/js9.0000000000002733↗
  9. Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer. First author DOI 10.1136/jitc-2023-008694↗
  10. Tumor Microenvironment Responsive CD8+ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Ca… First author DOI 10.1002/advs.202302498↗
  11. Current status and future perspectives of clinical research in pancreatic cancer: Establishment of evidence by science. First author DOI 10.1002/jhbp.1045↗
  12. Tumor-associated N1 and N2 neutrophils predict prognosis in patients with resected pancreatic ductal adenocarcinoma: A preliminary study. Co-author DOI 10.1002/mco2.183↗
  13. Deep insight into lymph node metastasis in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.ejso.2022.06.027↗
  14. A metabolism-relevant signature as a predictor for prognosis and therapeutic response in pancreatic cancer. Co-author DOI 10.1177/15353702211049220↗
  15. Commentary on "Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic C… First author DOI 10.1245/s10434-022-12148-1↗
  16. Lymph Node Metastatic Patterns and Survival Predictors Based on Tumor Size in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12325-021-01819-2↗
  17. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic c… Co-author DOI 10.1038/s41419-021-04293-4↗
  18. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer. Co-author DOI 10.1111/jcmm.15500↗
  19. Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70. Co-author DOI 10.1177/1758835920953728↗
  20. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Co-author DOI 10.1016/j.canlet.2019.06.013↗
  21. Independent effect of postoperative neutrophil-to-lymphocyte ratio on the survival of pancreatic ductal adenocarcinoma with open distal pancreatosplenectomy an… First author DOI 10.7150/jca.35856↗
  22. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. Co-author DOI 10.1186/s12967-018-1673-6↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ning Pu · 21 shared papers, 2018–2026 · strength 3.58
  2. Wenchuan Wu · 17 shared papers, 2018–2026 · strength 2.82
  3. Qiangda Chen · 15 shared papers, 2020–2026 · strength 2.56
  4. Wenhui Lou · 13 shared papers, 2020–2026 · strength 2.40
  5. Taochen He · 7 shared papers, 2024–2026 · strength 1.49
  6. Jun Yu · 9 shared papers, 2019–2026 · strength 1.41
  7. Wenhui Lou · 7 shared papers, 2018–2022 · strength 0.96
  8. Yun Jin · 4 shared papers, 2025–2026 · strength 0.83
  9. Shanshan Gao · 5 shared papers, 2019–2025 · strength 0.62
  10. Jiande Han · 3 shared papers, 2024–2025 · strength 0.60
  11. Jicheng Zhang · 3 shared papers, 2020–2026 · strength 0.57
  12. Huaxiang Xu · 3 shared papers, 2023–2025 · strength 0.56
  13. Joseph R. Habib · 3 shared papers, 2021–2025 · strength 0.48
  14. Liang Liu · 2 shared papers, 2025–2026 · strength 0.46
  15. Wenhui Lou · 2 shared papers, 2020–2026 · strength 0.43
  16. Yanfei An · 2 shared papers, 2025–2026 · strength 0.42
  17. Zhihang Xu · 2 shared papers, 2025 · strength 0.41
  18. Yaolin Xu · 2 shared papers, 2025 · strength 0.41
  19. Haibo Wang · 2 shared papers, 2025 · strength 0.41
  20. Dansong Wang · 4 shared papers, 2018–2021 · strength 0.37
  21. Dayong Jin · 4 shared papers, 2018–2021 · strength 0.37
  22. Tiantao Kuang · 4 shared papers, 2018–2021 · strength 0.37
  23. Wenquan Wang · 2 shared papers, 2023–2025 · strength 0.37
  24. Chenye Shi · 2 shared papers, 2023–2025 · strength 0.35
  25. Liang Liu · 2 shared papers, 2023–2025 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.